GET DAILY SIGNALSWhy Is Aethlon Medical (AEMD) Stock Up +374.13% Today?
Key Takeaways
- Aethlon Medical (AEMD) shares surged roughly 374%, closing at $6.78 versus a prior close of $1.43.
- The primary catalyst was a definitive all-stock merger agreement with privately held North Immunology, a clinical-stage immunology company.
- A concurrent, oversubscribed $180 million private placement drew backing from blue-chip healthcare investors to fund the combined pipeline.
- Legacy Aethlon stockholders will retain about 4.75% of the combined company, with North Immunology holders owning roughly 95.25%.
- Trading volume exploded to more than 25 million shares, far above the stock's typical daily turnover.
- Investors are now watching the deal's expected first-quarter 2027 closing and the planned clinical timeline for lead candidate NOR-101.
Opening Summary
Aethlon Medical, Inc. (AEMD), a San Diego-based clinical-stage company best known for its investigational Hemopurifier blood-filtration device, saw its shares skyrocket on Thursday, September 17, 2026. The stock closed at $6.78, up $5.35 from the prior session's close of $1.43 — a gain of approximately 374%. The move was driven almost entirely by the announcement that the company has agreed to merge with North Immunology, Inc., a private biotechnology firm, effectively pivoting the legacy device maker into a clinical-stage antibody developer.
The Merger With North Immunology
The dominant driver of the move was a definitive all-stock merger agreement with North Immunology, a privately held biotech focused on bispecific antibodies for inflammatory and immune diseases. Under the terms, Aethlon's wholly owned merger subsidiaries will combine the two businesses, and the surviving entity will operate as North Immunology, Inc., trading on the Nasdaq Capital Market under the ticker NRTX.
The structure makes clear which party is effectively acquiring the other. Pre-merger Aethlon stockholders are expected to own approximately 4.75% of the combined company, while North Immunology stockholders — including participants in the concurrent financing — will hold roughly 95.25%. The combined entity carries a pro forma equity value of approximately $346.5 million. Legacy AEMD holders will also receive contingent value rights tied to any future sale, license, or monetization of the legacy Hemopurifier business, providing a potential — but not assured — secondary path to value.
The $180 Million Private Placement
Backing the transaction is an oversubscribed private placement expected to raise approximately $180 million in gross proceeds, including the conversion of roughly $34 million of North Immunology's outstanding convertible promissory notes plus accrued interest, premiums, and fees. The financing drew support from a syndicate of healthcare-focused institutional investors, including Bain Capital Life Sciences, Janus Henderson Investors, Deep Track Capital, Longitude Capital, Soleus Capital, Invus, and Sirenia Capital Management, among others.
Management expects the proceeds to fund the combined company's operations into the second half of 2028 — a notable contrast to Aethlon's historically tight cash position as a sub-$10 million market-cap device developer. That financial runway was a key element of the market's enthusiastic response, signaling that the merged entity will have the resources to advance its clinical programs without immediate dilution risk.
The NOR-101 Pipeline Opportunity
At the center of the deal is NOR-101, North Immunology's lead candidate — a half-life-extended bispecific antibody targeting interleukin-13 (IL-13) and interleukin-18 (IL-18). The asset is being developed for atopic dermatitis and other immune-mediated conditions, and North Immunology has reported an extended half-life in a non-human primate pharmacokinetic study. The company plans to initiate a Phase 1a trial in the first quarter of 2027, followed by Phase 1b and Phase 2b studies in atopic dermatitis later that year, with topline data anticipated in 2028.
Market Context and Trading Activity
The surge was accompanied by extraordinary volume. More than 25 million shares changed hands during the session, a massive increase from the tens of thousands of shares traded in the days immediately prior. The stock opened sharply higher at $8.54, touched an intraday high of $9.50, and ultimately settled at $6.78, reflecting both intense initial buying interest and subsequent profit-taking as the session progressed.
The rally was idiosyncratic and deal-driven rather than a reflection of broader market conditions. Elevated short interest in the name — with a meaningful portion of the float held short before the announcement — likely amplified the upward move as short sellers scrambled to cover positions following the merger news. The move also broke decisively above the stock's recent trading range and its 50-day moving average, a technical shift consistent with the re-rating of the equity following the announcement.
What Comes Next for AEMD
The transaction remains subject to customary closing conditions, including approval by Aethlon stockholders, SEC registration, and Nasdaq listing clearance, with closing targeted for the first quarter of 2027. Until then, the shares will continue to trade under the AEMD symbol before the anticipated transition to NRTX.
Key uncertainties include the outcome of shareholder votes, the completion of the private placement, and the timing of regulatory clearances. The contingent value rights tied to the legacy Hemopurifier business carry no assured payout. Longer term, the combined company's value will hinge on execution of the NOR-101 clinical program, with early pharmacokinetic and safety data expected by mid-2027 and topline results from later-stage atopic dermatitis studies anticipated in 2028.
Trending AI Robots
For traders seeking to identify momentum across the market, Tickeron's Trending AI Robots page offers a curated view of the platform's strongest-performing AI trading bots under current market conditions. Tickeron provides hundreds of AI-driven trading bots covering thousands of tickers, with bots varying by strategy, timeframe, performance metrics, and traded symbols. Only the top performers are featured in the Trending AI Robots section, giving users a focused starting point for exploring automated trading strategies.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AEMD's RSI Indicator recovers from overbought zone
The 10-day RSI Indicator for AEMD moved out of overbought territory on October 02, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 18 instances where the indicator moved out of the overbought zone. In 18 of the 18 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 23 of 27 cases where AEMD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 85%.
The Moving Average Convergence Divergence Histogram (MACD) for AEMD turned negative on October 08, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 37 similar instances when the indicator turned negative. In 34 of the 37 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AEMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
AEMD broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for AEMD entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on AEMD as a result. In 54 of 71 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
Following a +3.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where AEMD advanced for three days, in 150 of 193 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.793) is normal, around the industry mean (4.170). P/E Ratio (-0.396) is within average values for comparable stocks, (1.500). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (2.111) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating fairly steady price growth. AEMD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AEMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of diagnostic and therapeutic device solutions for infectious disease, cancer and for other life threatening conditions
Industry MedicalNursingServices
Advertisement